Detail akcie Profusa Rg online

Business Summary: Profusa, Inc. is a commercial stage digital health company. The Company is engaged in the development of a new generation of biointegrated sensors that potentially empower the individual with the ability to monitor their body chemistry. The Company’s technology enables the development of bioengineered sensors that are designed to become one with the body to detect and continuously transmit actionable, clinical-grade data for personal and medical use. Its first clinical offering in the European Union, the Lumee Oxygen Platform, is designed to report reliable tissue oxygen levels in various regions of interest, both acutely and long-term. The Lumee Oxygen Platform has been designed for use in applications where monitoring of compromised tissue is beneficial, such as peripheral artery disease that results in narrowing of blood vessels and reduced blood flow to the lower limbs; chronic wounds (diabetic ulcers, pressure sores) that do not heal properly; and reconstructive surgery.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Profusa Inc revenues was not reported. Net loss increased from $1.1M to $31.5M. Higher net loss reflects Gain on the change in fair value of warr increase from $496K to $5.4M (expense), Change in fair value of convertible prom decrease from $141K (income) to $1.1M (expense), Formation and operating costs increase of 49% to $1.6M (expense).